The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease
Wollin L, Trinh MT, Zhang Y, Distler J (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 39
Pages Range: S134-S141
Journal Issue: 4
DOI: 10.55563/clinexprheumatol/g5mej7
Abstract
Objective. Interstitial lung disease (ILD) is a key driver of mortality in patients with systemic sclerosis (SSc). A lack of approved treatments encompasses a high unmet medical need. Nintedanib has recently been approved for treatment in SSc-associated ILD (SSc-ILD) following SENSCIS (R), a Phase III clinical trial showing that nintedanib slows the loss of pulmonary function in patients with SSc-ILD relative to placebo, as measured by annual rate of decline in forced vital capacity over 52 weeks. The aim of this study was to compare the activity of nintedanib and mycophenolate mofetil (MMF) in a transgenic Fra2 mouse model of SSc-ILD.
Authors with CRIS profile
Minh Thuong Trinh
Department of Medicine 3 – Rheumatology and Immunology
Yun Zhang
Department of Medicine 3 – Rheumatology and Immunology
Jörg Distler
Professur für Molekulare Mechanismen der Organfibrose
Involved external institutions
Germany (DE)How to cite
APA:
Wollin, L., Trinh, M.T., Zhang, Y., & Distler, J. (2021). The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 39(4), S134-S141. https://doi.org/10.55563/clinexprheumatol/g5mej7
MLA:
Wollin, Lutz, et al. "The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease." Clinical and Experimental Rheumatology 39.4 (2021): S134-S141.
BibTeX: Download